BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors

Neoplasms Clinical Trial

Official title:

A Phase I Open-label Dose Escalation Study of Single Oral Daily Doses of BIBW 2992 for Three Days After Administration of Docetaxel, in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02171676
• Other study ID #: 1200.20
• Status: Completed
• Phase: Phase 1
• First received: June 20, 2014
• Last updated: June 20, 2014
• Start date: May 2005

Study information

• Verified date: June 2014
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Health authority: Belgium: Federal Agency for Medicines and Health Products, FAMHP
• Study type: Interventional

Clinical Trial Summary

Maximum tolerated dose (MTD), safety, pharmacokinetic and pharmacodynamic parameters, and efficacy of pulsatile administration of BIBW 2992 in combination with docetaxel (Taxotere®)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. primary completion date: March 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female patients with confirmed diagnosis of advanced, non resectable and / or metastatic solid tumors, of types historically known to express EGFR and/or HER2, who have failed conventional treatment, or for whom no therapy of proven efficacy exists, or who are not amenable to established forms of treatment preferably patients with breast, prostate, or ovarian cancer. In addition, patients with a disease amenable for standard treatment with docetaxel

• Age 18 years or older

• Life expectancy of at least three (3) months

• Written informed consent that is consistent with International Conference on Harmonization - Good Clinical Practice guidelines

• Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1

• Patients recovered (Common Terminology Criteria (CTC) Grade 0 or 1) from any therapy-related toxicities from previous chemo-, hormone-, immuno-, or radiotherapies

• Patients recovered from previous surgery

The 12 additional patients recruited at the MTD must also meet the following criteria:

• Measurable tumor deposits (Response Evaluation Criteria in Solid Tumors) by one or more techniques (X-ray, CT, MRI) and/or recognized tumor markers such as prostate specific antigen (prostate cancer) or cancer antigen 125 (Ovarian cancer)

Exclusion Criteria:

• Active infectious disease

• Gastrointestinal disorders that might interfere with the absorption of the study drug or chronic diarrhea

• Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the protocol

• Patients with untreated or symptomatic brain metastases. Patients with treated, asymptomatic brain metastases are eligible if there has been no change in brain disease status for at least eight weeks, no history of cerebral edema or bleeding in the past eight weeks and no requirement for steroids or anti-epileptic therapy

• Cardiac left ventricular function with resting ejection fraction CTC = Grade 1

• Absolute neutrophil count (ANC) less than 1500 / mm3

• Platelet count less than 100 000 / mm3

• Bilirubin > upper limit of normal (ULN)

• Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) > 1.5 x ULN

• Alkaline Phosphatase > 2.5 x ULN

• Serum creatinine > 1.5 mg / dl (> 132 µmol / L, SI (Système Internationale) unit equivalent)

• Women and men sexually active and unwilling to use a medically acceptable method of contraception

• Pregnancy or breast-feeding

• Treatment with other investigational drugs; chemotherapy, immunotherapy, radiotherapy or hormone therapy (excluding luteinising hormone-releasing hormone agonists, other hormones taken for breast cancer, or bisphosphonates) or participation in another clinical study within the past four weeks before start of therapy or concomitantly with this study

• Treatment with an EGFR- or HER2 inhibiting drug within the past four weeks before start of therapy or concomitantly with this study (8 weeks for trastuzumab)

• Patients unable to comply with the protocol

• Active alcohol or drug abuse

• Hypersensitivity to docetaxel or any component or other drug formulated with polysorbate 80

The patient may be eligible for re-treatment after the previous course is finished. The patient will not be eligible if any of the following conditions are met:

• If patients latest X-ray, CT or MRI reveals progressive disease, or if clinical assessment reveals signs of disease progression

• Cardiac left ventricular function CTC Grade = 2 at any time during the previous course

• Patients fulfilling any of the Exclusion Criteria listed before as determined on day 18 of the treatment course 1 (visit 7) or day 18 (visit R5) of the previous course

• Patients not recovered from any dose-limiting toxicity (DLT) 14 days after onset. Recovery is defined as a return to baseline level or CTC Grade <= 1, whichever is higher

Study Design

Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Neoplasms

Intervention

Drug:
• Docetaxel

• BIBW 2992

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose (MTD)		up to 168 days	No
Primary	Incidence and intensity of adverse events according to Common Terminology Criteria for Adverse Events (CTCAE version 3.0)		up to 35 months	Yes
Secondary	Area under the plasma concentration-time curve (AUC) for different time points		up to 48 hours after the first drug administration	No
Secondary	Percentage of AUC0-8 that is obtained by extrapolation (%AUC0-tz)		up to 48 hours after the first drug administration	Yes
Secondary	Pre-dose plasma concentration (Cpre)		pre-dose on day 3 and 4	No
Secondary	Plasma concentration at 24 h following the first (C24,1) dose		24 hours after the first drug administration	No
Secondary	Maximum measured plasma concentration (Cmax)		up to 48 hours after the first drug administration	No
Secondary	Time from dosing to the maximum plasma concentration following the first dose of uniform intervals t (tmax)		up to 48 hours after the first drug administration	No
Secondary	Terminal rate constant in plasma (?z )		up to 48 hours after the first drug administration	No
Secondary	Terminal half-life (t1/2)		up to 48 hours after the first drug administration	No
Secondary	Mean residence time after oral administration (MRTpo)		up to 48 hours after the first drug administration	No
Secondary	Apparent clearance (CL/F)		up to 48 hours after the first drug administration	No
Secondary	Apparent volume of distribution (V) for different time points		up to 48 hours after the first drug administration	No
Secondary	Modulation of biomarkers (EGFR (Epidermal growth factor receptor), p-EGFR, p-MAPK (mitogen-activated protein kinase), p-Akt, Ki 67, p27Kip1) in skin biopsies		Baseline and day 4	No
Secondary	Modulation of biomarkers (EGFR, p-EGFR, HER2 (Human epidermal growth factor receptor), p-MAPK, p-Akt, Ki 67, p27Kip1) in tumour biopsies in 6 or more patients treated at the MTD		Baseline and day 4	No
Secondary	Objective tumor response		up to 35 months	No
Secondary	Correlation of EGFR, HER2, estrogen receptor (ER) and progesterone receptor (PrR) immunohistochemical status as based on tumor biopsies, or excisions obtained prior to this trial, with objective tumor responses		up to 35 months	No

External Links

•   Link